#2469 - Brigham Buhler

Brigham Buhler discusses ongoing efforts to reclassify peptides as safe under new FDA leadership, including RFK Jr. as HHS Secretary, after the prior administration banned 19 peptides without responding to safety inquiries. He shares personal health improvements from peptides and highlights their role in proactive care, contrasting this with a sick-care system profiting from chronic disease.

Hormone Myths and Optimization
Testosterone does not cause prostate cancer; fears stem from a 1930s study of three patients, one chemically castrated, debunked since the 1990s yet perpetuated as dogma. Optimal levels saturate prostate receptors and may reduce cancer risk, as shown by unchanged prevalence despite widespread TRT use. FDA is removing black-box warnings on hormones, emphasizing their role in healthspan amid natural declines in midlife.

Peptides, Compounding, and Big Pharma Conflicts
Peptides like BPC-157 occur naturally, backed by 800+ studies and real-world use in 90,000+ patients without major adverse events. Bans arose from GLP-1 lobbying by pharma giants protecting patents, despite compounders filling shortages legally. Black/gray markets now dominate (4/5 peptides), risking improper dosing; solution is clinician oversight via compounding pharmacies, not billion-dollar approvals for cash-pay tools.